Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 30;12(1):711.
doi: 10.1186/s13104-019-4753-7.

Measurement of serum tenascin-X in patients with congenital adrenal hyperplasia at risk for Ehlers-Danlos contiguous gene deletion syndrome CAH-X

Affiliations

Measurement of serum tenascin-X in patients with congenital adrenal hyperplasia at risk for Ehlers-Danlos contiguous gene deletion syndrome CAH-X

Vipula Kolli et al. BMC Res Notes. .

Abstract

Objective: Approximately 10% of patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency carry a mutation that disrupts CYP21A2 and the flanking TNXB gene resulting in CAH-X, a contiguous gene deletion syndrome. TNXB encodes tenascin-X (TNX), an extracellular matrix glycoprotein that plays an important role in collagen organization. TNXB impairment is associated with Ehlers-Danlos syndrome. Symptoms include joint hypermobility, hernias and cardiac defects. We measured serum TNX using an antibody targeting the amino-terminal of the TNX protein in 161 subjects, including extensively genotyped and phenotyped CAH patients, their relatives, and healthy controls.

Results: We evaluated the potential of serum TNX as a screening tool for CAH-X. CAH-X patients, especially haploinsufficient patients carrying the TNXA-TNXB chimeric gene CAH-X-CH-1 showed reduced TNX levels compared to controls (P < 0.05). TNX levels were similar in all subjects carrying a TNXB mutation. However, CAH patients who did not harbor a TNXB mutation also had reduced TNX compared to controls (P < 0.001). Thus, measuring serum TNX is not an effective screen for CAH-X amongst patients with CAH. TNXB genotyping is recommended for CAH patients who have symptoms of a connective tissue disorder. Epigenetic factors that influence TNX expression require further study.

Keywords: CYP21A2; Congenital adrenal hyperplasia; Ehlers–Danlos syndrome; TNXB; Tenascin-X.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Serum tenascin-X in healthy volunteers, patients with CAH and different CAH-X patient groups. Box plots represent the median (interquartile range) of absolute serum TNX concentrations. *P < 0.05, **P < 0.001, as determined by Kruskal–Wallis test. Comparisons between other groups were not significant
Fig. 2
Fig. 2
Serum tenascin-X according to the CAH phenotype. Box plots represent the median (interquartile range) of absolute serum TNX concentrations. SW: salt-walting, SV: simple virilizing, NC: non-classic

Similar articles

Cited by

References

    1. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390(10108):2194–2210. doi: 10.1016/S0140-6736(17)31431-9. - DOI - PubMed
    1. Speiser PW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043–4088. doi: 10.1210/jc.2018-01865. - DOI - PMC - PubMed
    1. Hannah-Shmouni F, et al. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med. 2017;19(11):1276–1279. doi: 10.1038/gim.2017.46. - DOI - PMC - PubMed
    1. Morel Y, et al. Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus. Proc Natl Acad Sci USA. 1989;86(17):6582–6586. doi: 10.1073/pnas.86.17.6582. - DOI - PMC - PubMed
    1. Bristow J, et al. Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol. 1993;122(1):265–278. doi: 10.1083/jcb.122.1.265. - DOI - PMC - PubMed

MeSH terms

Supplementary concepts